A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.

Bailin He,Qiang Wang,Xiaoli Liu,Ziyuan Lu,Jiaochan Han,Chengyun Pan,Bing Z Carter,Qifa Liu,Na Xu,Hongsheng Zhou

Biomedicine & Pharmacotherapy（2020）

引用 13|浏览85

暂无评分

摘要

•HDAC inhibitor chidamide enhances imatinib-induced CML cell death in vitro.•Combined inhibition of HDAC and Bcr-Abl overcomes TKI-resistance in CML.•Upregulation of β-catenin in drug-resistant CML is inhibited by the co-treatment.•This combination effectively targets CD34+ stem cells from BC-CML patients.

查看译文

关键词

Chronic myeloid leukemia,HDAC inhibitor,Chidamide,β-catenin,Drug resistance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要